Tumor activated antibodies targeting cd3 and uses thereof
HK40135172APending Publication Date: 2026-07-17JANUX THERAPEUTICS INC
Patent Information
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- JANUX THERAPEUTICS INC
- Filing Date
- 2026-05-19
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing CD3-targeting antibodies are difficult to activate effectively in the tumor microenvironment, resulting in poor treatment outcomes.
Method used
A separate polypeptide or polypeptide complex A1-L1-P1 was designed, wherein A1 contains a recombinant antibody or its antigen-binding fragment, which binds to the CD3 domain, and P1 is a substrate of a tumor-specific protease. The antibody is activated by the cleavage of P1 by the tumor-specific protease, which causes P1 to dissociate from CD3.
Benefits of technology
This study achieved effective activation of CD3-targeting antibodies in the tumor microenvironment, enhancing therapeutic efficacy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
Disclosed herein are recombinant antibodies, or antigen-binding fragments thereof, comprising CD3 binding domains that have been optimized via alanine scanning mutagenesis. In some embodiments, the recombinant antibody or antigen-binding fragment thereof further comprises an antigen-binding domain.
Need to check novelty before this filing date? Find Prior Art